CA3121755A1 - Ire1 small molecule inhibitors - Google Patents

Ire1 small molecule inhibitors Download PDF

Info

Publication number
CA3121755A1
CA3121755A1 CA3121755A CA3121755A CA3121755A1 CA 3121755 A1 CA3121755 A1 CA 3121755A1 CA 3121755 A CA3121755 A CA 3121755A CA 3121755 A CA3121755 A CA 3121755A CA 3121755 A1 CA3121755 A1 CA 3121755A1
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
c4alkyl
pharmaceutically acceptable
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3121755A
Other languages
English (en)
French (fr)
Inventor
Joseph P. Vacca
Sarah Bettigole
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of CA3121755A1 publication Critical patent/CA3121755A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3121755A 2018-12-03 2019-12-02 Ire1 small molecule inhibitors Abandoned CA3121755A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862774794P 2018-12-03 2018-12-03
US62/774,794 2018-12-03
PCT/US2019/063921 WO2020117635A1 (en) 2018-12-03 2019-12-02 Ire1 small molecule inhibitors

Publications (1)

Publication Number Publication Date
CA3121755A1 true CA3121755A1 (en) 2020-06-11

Family

ID=69024615

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3121755A Abandoned CA3121755A1 (en) 2018-12-03 2019-12-02 Ire1 small molecule inhibitors

Country Status (8)

Country Link
US (1) US12071426B2 (https=)
EP (1) EP3891137B1 (https=)
JP (1) JP7546299B2 (https=)
AU (1) AU2019393754A1 (https=)
CA (1) CA3121755A1 (https=)
IL (1) IL283433A (https=)
SG (1) SG11202105690TA (https=)
WO (1) WO2020117635A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI831829B (zh) 2018-09-12 2024-02-11 美商建南德克公司 苯氧基-吡啶基-嘧啶化合物及使用方法
EP3891137B1 (en) 2018-12-03 2024-10-09 Cornell University Ire1 small molecule inhibitors
JP7539892B2 (ja) 2019-01-03 2024-08-26 ジェネンテック, インコーポレイテッド 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素i(ireiアルファ)の阻害剤としてのピリド-ピリミジノン化合物及びプテリジノン化合物
CN113795307A (zh) * 2019-02-18 2021-12-14 基因泰克公司 吡啶并嘧啶基化合物及其使用方法
WO2020232403A1 (en) * 2019-05-15 2020-11-19 Cornell University Treatment of fibrosis with ire1 small molecule inhibitors
WO2020252165A1 (en) * 2019-06-11 2020-12-17 Genentech, Inc. Quinazolinyl compounds and methods of use
US11840523B2 (en) * 2020-11-13 2023-12-12 The Regents Of The University Of California IRE1α inhibitors and uses thereof
MX2023005747A (es) 2020-11-18 2023-07-28 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.
KR20240113496A (ko) 2021-12-03 2024-07-22 데시페라 파마슈티칼스, 엘엘씨. Gcn2 및 perk 키나아제 억제제로서의 헤테로고리 화합물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
EP3548476A4 (en) * 2016-12-02 2020-05-20 Quentis Therapeutics, Inc. SMALL MOLECULAR IRE1 INHIBITORS
CN108239074B (zh) 2016-12-26 2021-07-06 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
AR111281A1 (es) * 2017-03-17 2019-06-26 Genentech Inc Compuestos de pirimidinil-piridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
CA3064837A1 (en) * 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
US10745379B2 (en) * 2017-11-10 2020-08-18 Cornell University IRE1 small molecule inhibitors
EP3891137B1 (en) 2018-12-03 2024-10-09 Cornell University Ire1 small molecule inhibitors

Also Published As

Publication number Publication date
US20220356168A1 (en) 2022-11-10
SG11202105690TA (en) 2021-06-29
JP2022511477A (ja) 2022-01-31
JP7546299B2 (ja) 2024-09-06
EP3891137B1 (en) 2024-10-09
AU2019393754A1 (en) 2021-07-22
US12071426B2 (en) 2024-08-27
IL283433A (en) 2021-07-29
EP3891137A1 (en) 2021-10-13
WO2020117635A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
CA3121755A1 (en) Ire1 small molecule inhibitors
US12071424B2 (en) IRE1 small molecule inhibitors
US10934275B2 (en) IRE1 small molecule inhibitors
US10633342B2 (en) Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2018222918A1 (en) Ire1 small molecule inhibitors
US20210290613A1 (en) Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2018222917A1 (en) Ire1 small molecule inhibitors
WO2017096045A1 (en) Multivalent ras binding compounds
US12479818B2 (en) Treatment of fibrosis with IRE1 small molecule inhibitors
EP4201924B1 (en) Ire1 small molecule inhibitors
US11649212B2 (en) Inhibitors of indoleamine 2,3-dioxygenase and methods of their use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210824

FZDE Discontinued

Effective date: 20240221